Perspective Therapeutics, Inc. (NYSE:CATX) Receives $15.13 Consensus Target Price from Brokerages

Perspective Therapeutics, Inc. (NYSE:CATX) has received a consensus recommendation of “Buy” from the twelve brokerages that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, eight have assigned a buy recommendation and three have given a strong buy recommendation to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $14.56.

Several research analysts have recently commented on CATX shares. Scotiabank started coverage on Perspective Therapeutics in a research note on Friday, March 7th. They set a “sector outperform” rating and a $15.00 target price for the company. HC Wainwright began coverage on Perspective Therapeutics in a research note on Thursday. They issued a “buy” rating and a $10.00 price target for the company. Brookline Capital Management upgraded Perspective Therapeutics to a “strong-buy” rating in a research note on Monday, March 10th. Oppenheimer reduced their price target on Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating for the company in a research note on Friday, November 22nd. Finally, Lifesci Capital upgraded Perspective Therapeutics to a “strong-buy” rating in a research note on Thursday, March 6th.

Hedge Funds Weigh In On Perspective Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CATX. Y Intercept Hong Kong Ltd acquired a new position in shares of Perspective Therapeutics during the 4th quarter worth $33,000. Aigen Investment Management LP acquired a new position in shares of Perspective Therapeutics during the 4th quarter worth $34,000. National Bank of Canada FI raised its holdings in shares of Perspective Therapeutics by 549,900.0% during the 4th quarter. National Bank of Canada FI now owns 11,000 shares of the company’s stock worth $35,000 after buying an additional 10,998 shares in the last quarter. ProShare Advisors LLC raised its holdings in shares of Perspective Therapeutics by 49.1% during the 4th quarter. ProShare Advisors LLC now owns 15,225 shares of the company’s stock worth $49,000 after buying an additional 5,011 shares in the last quarter. Finally, Vontobel Holding Ltd. acquired a new position in shares of Perspective Therapeutics during the 4th quarter worth $51,000. 54.66% of the stock is owned by institutional investors and hedge funds.

Perspective Therapeutics Trading Down 1.1 %

Shares of NYSE CATX opened at $2.59 on Monday. Perspective Therapeutics has a 12 month low of $2.32 and a 12 month high of $19.05. The stock has a 50 day moving average of $3.14 and a 200-day moving average of $7.32.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.